MCID: LMT001
MIFTS: 47

Limited Scleroderma

Categories: Bone diseases, Immune diseases, Nephrological diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Limited Scleroderma

MalaCards integrated aliases for Limited Scleroderma:

Name: Limited Scleroderma 12 15 17
Limited Cutaneous Systemic Sclerosis 12 52 58
Systemic Sclerosis Sine Scleroderma 52 58 71
Limited Cutaneous Systemic Scleroderma 52 58
Limited Systemic Sclerosis 52 58
Scleroderma, Limited 43 71
Progressive Systemic Sclerosis Sine Scleroderma 52
Systemic Sclerosis, Limited 12
Scleroderma, Sine 52
Crest Syndrome 71

Characteristics:

Orphanet epidemiological data:

58
limited cutaneous systemic sclerosis
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult; Age of death: adult;
limited systemic sclerosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:1577
MeSH 43 D045745
ICD10 via Orphanet 33 M34.0 M34.1
UMLS 71 C0206138 C0748540 C1290138

Summaries for Limited Scleroderma

NIH Rare Diseases : 52 Limited cutaneous systemic sclerosis is a subtype of systemic sclerosis characterized by the association of Raynaud's phenomenon and skin fibrosis on the hands, face, feet and forearms. The exact cause of limited cutaneous systemic sclerosis is unknown, but likely originates from an autoimmune reaction which leads to overproduction of collagen. In some cases, the condition is associated with exposure to certain chemicals. Management is aimed at treating the symptoms present in each affected individual.

MalaCards based summary : Limited Scleroderma, also known as limited cutaneous systemic sclerosis, is related to crest syndrome and scleroderma, familial progressive. An important gene associated with Limited Scleroderma is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are IL12-mediated signaling events and Innate Lymphoid Cell Differentiation Pathways. The drugs Ropivacaine and Anesthetics, Local have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are hypopigmented skin patches and autoimmunity

Related Diseases for Limited Scleroderma

Diseases related to Limited Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 crest syndrome 32.9 TOP1 SNRNP70 EXOSC10 CENPS CENPC CENPB
2 scleroderma, familial progressive 31.4 TOP1 CENPB CCN2
3 systemic scleroderma 31.2 TSSK1B TRIM21 TOP1 SNRNP70 IRF5 EXOSC10
4 juvenile rheumatoid arthritis 30.9 IL2RA IL2 HLA-DRB1
5 primary biliary cirrhosis 30.7 IRF5 IL2RA IL2 HLA-DRB1 CENPB
6 diffuse cutaneous systemic sclerosis 30.7 IRF5 IFI16 HLA-DRB1 CCR6 CCN2 CAV1
7 lupus erythematosus 30.6 TRIM21 SNRNP70 IRF5 HLA-DRB1
8 rheumatic disease 30.6 TRIM21 TOP1 IL2RA HLA-DRB1 CENPB CENPA
9 raynaud disease 30.5 TRIM21 TOP1 SNRNP70 CENPB CENPA
10 telangiectasis 30.5 TRIM21 TOP1 SNRNP70 EXOSC10 CENPS CENPB
11 gastric antral vascular ectasia 30.4 TOP1 CENPS
12 connective tissue disease 30.4 TOP1 SNRNP70 IL2 HLA-DRB1 CENPC CENPB
13 diffuse scleroderma 30.3 TSSK1B TRIM21 TOP1 SNRNP70 EXOSC10 CENPB
14 sjogren syndrome 30.3 TRIM21 IL2RA CENPB
15 autoimmune disease 30.2 TRIM21 IRF5 IL2RA IL2 HLA-DRB1 CENPB
16 collagen disease 29.9 TSSK1B TRIM21 TOP1 SNRNP70 IRF5 EXOSC10
17 systemic lupus erythematosus 29.9 TRIM21 SNRNP70 KIAA0319L IRF5 IL2RA IL2
18 reynolds syndrome 11.5
19 telangiectasia, hereditary hemorrhagic, type 4 11.3
20 recurrent respiratory papillomatosis 10.7 IL2 HLA-DRB1
21 tuberculoid leprosy 10.7 IL2RA IL2 CCR6
22 t-cell adult acute lymphocytic leukemia 10.7 IL2RA IL2 CCR6
23 red cell aplasia 10.7 IL2RA IL2 HLA-DRB1
24 pars planitis 10.6 IL2 HLA-DRB1 CCR6
25 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.6 IL2RA IL2 CCR6
26 conjunctival vascular disease 10.6 TRIM21 TOP1
27 pure red-cell aplasia 10.6 IL2RA IL2 HLA-DRB1
28 posterior uveitis 10.6 IL2RA IL2 CCR6
29 autoimmune gastritis 10.6 IL2 HLA-DRB1 CCR6
30 rheumatoid factor-negative juvenile idiopathic arthritis 10.6 IL2RA HLA-DRB1
31 autoimmune disease of gastrointestinal tract 10.6 IL2 HLA-DRB1 CCR6
32 pulmonary sarcoidosis 10.6 IL2RA IL2 CCR6
33 pulmonary arterial hypertension associated with congenital heart disease 10.6 CCN2 CAV1
34 intermediate uveitis 10.6 IL2RA IL2 HLA-DRB1 CCR6
35 facial hemiatrophy 10.6 SNRNP70 EXOSC10
36 autoimmune disease of urogenital tract 10.6 TRIM21 IRF5 CCR6
37 autoimmune disease of endocrine system 10.6 IL2RA IL2 HLA-DRB1 CCR6
38 lymph node disease 10.6 TRIM21 IL2 CCR6
39 exanthem 10.6 TRIM21 IL2 CCR6
40 mumps 10.6 IL2RA IL2 HLA-DRB1
41 leprosy 3 10.6 IL2 HLA-DRB1 CCR6
42 sarcoidosis 1 10.6 IL2RA IL2 HLA-DRB1 CCR6
43 rubella 10.6 IL2RA IL2 HLA-DRB1
44 trochlear nerve disease 10.6 TRIM21 HLA-DRB1
45 adult t-cell leukemia 10.6 IL2RA IL2 CCR6
46 crohn's disease 10.6 IRF5 IL2 HLA-DRB1 CCR6
47 vernal conjunctivitis 10.6 IL2RA CCR6
48 sezary's disease 10.6 IL2RA IL2 CCR6
49 behcet syndrome 10.6 IL2RA IL2 HLA-DRB1 CCR6
50 ulcerative colitis 10.5 IRF5 IL2 HLA-DRB1 CCR6

Graphical network of the top 20 diseases related to Limited Scleroderma:



Diseases related to Limited Scleroderma

Symptoms & Phenotypes for Limited Scleroderma

Human phenotypes related to Limited Scleroderma:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypopigmented skin patches 58 31 hallmark (90%) Very frequent (99-80%) HP:0001053
2 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
3 narrow foramen obturatorium 58 31 hallmark (90%) Very frequent (99-80%) HP:0100958
4 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
5 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
6 gastroesophageal reflux 58 31 frequent (33%) Frequent (79-30%) HP:0002020
7 telangiectasia of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0100585
8 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
9 mucosal telangiectasiae 58 31 frequent (33%) Frequent (79-30%) HP:0100579
10 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
11 pulmonary arterial hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002092
12 contractures involving the joints of the feet 58 31 occasional (7.5%) Occasional (29-5%) HP:0008366
13 joint contracture of the hand 58 31 occasional (7.5%) Occasional (29-5%) HP:0009473
14 abnormality of skin pigmentation 58 Very frequent (99-80%)
15 abnormality of the skin 58 Very frequent (99-80%)

Drugs & Therapeutics for Limited Scleroderma

Drugs for Limited Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2 Anesthetics, Local Phase 4
3 Anesthetics Phase 4
4 Central Nervous System Depressants Phase 4
5
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
6
Sodium citrate Approved, Investigational Phase 3 68-04-2
7
Bupivacaine Approved, Investigational Phase 2, Phase 3 38396-39-3, 2180-92-9 2474
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
9
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
10 Anti-Arrhythmia Agents Phase 2, Phase 3
11 Pharmaceutical Solutions Phase 2, Phase 3
12 Sodium Channel Blockers Phase 2, Phase 3
13 Diuretics, Potassium Sparing Phase 2, Phase 3
14 Vasodilator Agents Phase 3
15 Citrate Phase 3
16 Chelating Agents Phase 3
17 Anticoagulants Phase 3
18 Sildenafil Citrate Phase 3 171599-83-0
19 Phosphodiesterase 5 Inhibitors Phase 3
20 Phosphodiesterase Inhibitors Phase 3
21 Calcium, Dietary Phase 3
22
Treprostinil Approved, Investigational Phase 2 81846-19-7 54786 6918140
23 Tezosentan Investigational Phase 2 180384-57-0
24 Ifetroban Investigational Phase 2 143443-90-7
25 Antihypertensive Agents Phase 2
26 Platelet Aggregation Inhibitors Phase 2
27
Epinephrine Approved, Vet_approved 51-43-4 5816
28
Racepinephrine Approved 329-65-7 838
29
Nitric Oxide Approved 10102-43-9 145068
30 Hormones
31 Epinephryl borate
32 Analgesics, Opioid
33 Analgesics
34 Neurotransmitter Agents
35 Respiratory System Agents
36 Anti-Asthmatic Agents
37 Autonomic Agents
38 Free Radical Scavengers
39 Antioxidants
40 Protective Agents
41 Bronchodilator Agents

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Intérêt du TFP (Transversalis Fascia Plane) Bloc échoguidé Pour l'analgésie du prélèvement Osseux de crête Iliaque Completed NCT02398474 Phase 4 TFP block ropivacaine;ropivacaine infiltration of the iliac crest bone
2 Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
3 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
4 Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
5 DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
6 Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study With P144 Topical Adminsitration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00781053 Phase 2 P144 cream
7 Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00574613 Phase 2 P144;placebo
8 A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Recruiting NCT03919799 Phase 2 KD025;Placebo
9 A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH) Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
10 Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers. Completed NCT00656825 Phase 1 P144 cream;P144 cream;P144 cream;Placebo
11 A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial Recruiting NCT03145298 Phase 1
12 Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients Active, not recruiting NCT01655836 Phase 1
13 Comparative Clinical Study of the Prevention of the Reduction of Alveolar Crest by Alveoli Filling With an Injectable Calcium Phosphate After Extraction of Mandibular Molar or Pre Molar Unknown status NCT00740311
14 A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma Completed NCT01881529
15 A Multicenter, Prospective Cohort Study Using Nailfold VideoCAPillaroscopy(NVC) and Other Factors to Determine the Risk of Developing Digital Ulceration in Patients With Systemic Sclerosis (SSc) Completed NCT01377090
16 The Analgesic Efficacy of the Transversalis Fascia Plane Block in Iliac Crest Bone Graft Harvesting Completed NCT01133730 Active treatment;Placebo Arm
17 A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler Completed NCT00837473
18 Metabolomic Analysis of Systemic Sclerosis Recruiting NCT02298777
19 Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. Recruiting NCT03211325
20 A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis Active, not recruiting NCT03889509
21 Localized Effects of Photobiomodulation and Exogenous Nitric Oxide on CREST Patients Calcinosis Cutis & Raynaud Phenomenon Not yet recruiting NCT03972566 INOMAX
22 A Multicenter, Prospective, Longitudinal Study to Evaluate Gastrointestinal Function and Clinical and Molecular Biomarkers in Subjects With Early and Late Diffuse Cutaneous Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis, and Healthy Volunteers Withdrawn NCT02531009

Search NIH Clinical Center for Limited Scleroderma

Cochrane evidence based reviews: scleroderma, limited

Genetic Tests for Limited Scleroderma

Anatomical Context for Limited Scleroderma

MalaCards organs/tissues related to Limited Scleroderma:

40
Skin, Bone, T Cells, Lung, Thyroid, Endothelial, Heart

Publications for Limited Scleroderma

Articles related to Limited Scleroderma:

(show top 50) (show all 220)
# Title Authors PMID Year
1
Calcinosis Cutis as the Initial Manifestation of Limited Scleroderma. 61
31985726 2020
2
Pauci-Immune Necrotizing Glomerulonephritis as a Manifestation of Systemic Sclerosis Sine Scleroderma. 61
31789998 2019
3
Periostin is induced by IL-4/IL-13 in dermal fibroblasts and promotes RhoA/ROCK pathway-mediated TGF-β1 secretion in abnormal scar formation. 61
31066603 2019
4
The evaluation of a home-based program for hands in patients with systemic sclerosis. 61
29198478 2019
5
Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. 61
30535994 2019
6
Chronic Eroded Perianal Plaque in a Patient with Limited Systemic Scleroderma. 61
31782710 2019
7
Involvement of Periostin in Skin Function and the Pathogenesis of Skin Diseases. 61
31037628 2019
8
Connective Tissue Disease: Current Concepts. 61
30466687 2019
9
Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. 61
29655520 2018
10
Anti-RO 52-positive systemic sclerosis sine scleroderma with multisystem involvement and recurrent vasculitis. 61
30073982 2018
11
Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register. 61
29573101 2018
12
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. 61
29678941 2018
13
Systemic Sclerosis Sine Scleroderma in Mexican Patients. Case Reports. 61
28065485 2018
14
[RHEOLOGICAL PROPERTIES OF BLOOD SERUM AT SYSTEMIC SCLEROSIS]. 61
29697389 2018
15
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. 61
30013378 2018
16
Cutaneous calcinosis in a patient with limited scleroderma: CREST Syndrome. 61
29308290 2017
17
Periostin in the pathogenesis of skin diseases. 61
28916993 2017
18
Upper gastrointestinal bleeding (watermelon stomach) in a patient with limited scleroderma (CREST syndrome). 61
27353193 2017
19
Choroidal and central foveal thickness in patients with scleroderma and its systemic associations. 61
27864836 2017
20
[Research of systemic sclerosis sine scleroderma]. 61
28870043 2017
21
Systemic sclerosis sine scleroderma. 61
29068586 2017
22
The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 61
28426903 2017
23
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. 61
28671485 2017
24
Scleroderma Induced by Pembrolizumab: A Case Series. 61
28599746 2017
25
Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature. 61
28440561 2017
26
Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key? 61
27340761 2017
27
Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension. 61
27052360 2016
28
Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells. 61
26677892 2016
29
Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma. 61
26714268 2016
30
Fibrillary glomerulonephritis associated with limited scleroderma: a case report. 61
26709524 2016
31
Systemic sclerosis - a multi-purpose use of ultrasound: Editorial comment on: G. Pracoń, M. Płaza, M. Walentowska-Janowicz, I. Sudoł-Szopińska The value of ultrasound in the diagnosis of limited scleroderma - a case report. 61
27104009 2016
32
Polymyositis and the Spectrum of Scleroderma Disorders. 61
30755854 2016
33
Development of systemic sclerosis in patients with autoimmune hepatitis: an emerging overlap syndrome. 61
27458514 2016
34
A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma. 61
27559487 2016
35
The value of ultrasound in the diagnosis of limited scleroderma - a case report. 61
26675049 2015
36
Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. 61
26242276 2015
37
Systemic sclerosis sine scleroderma: a case report of anterior uveitis. 61
26150271 2015
38
Multiple intracerebral hemorrhages in a patient with systemic sclerosis sine scleroderma. 61
24993862 2015
39
[Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil]. 61
25559063 2015
40
Osteonecrosis of multiple joints in a patient with limited scleroderma/CREST syndrome. 61
25807102 2015
41
[Usefulness of gastric emptying scintigraphy for the evaluation and management of scleroderma related gastroparesis]. 61
26076515 2015
42
Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy. 61
26223094 2015
43
Systemic Sclerosis Sine Scleroderma. 61
26259425 2014
44
Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. 61
25274885 2014
45
Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences. 61
24776173 2014
46
[Diffuse interstitial pneumonia revealing systemic sclerosis sine scleroderma]. 61
25775296 2014
47
Improved survival in limited scleroderma-related pulmonary artery hypertension. 61
23361526 2014
48
Pulsed versus continuous wave low-level light therapy on osteoarticular signs and symptoms in limited scleroderma (CREST syndrome): a case report. 61
25393970 2014
49
A case of sine scleroderma with parenchymal lung disease. 61
24627847 2014
50
Limited scleroderma with pauci-immune glomerulonephritis in the presence of renal cell carcinoma. 61
23656799 2013

Variations for Limited Scleroderma

Expression for Limited Scleroderma

Search GEO for disease gene expression data for Limited Scleroderma.

Pathways for Limited Scleroderma

Pathways related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.38 IL2RA IL2 HLA-DRB1
2 11.03 IL2RA IL2 CCR6
3 10.25 IL2RA IL2 HLA-DRB1

GO Terms for Limited Scleroderma

Cellular components related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.72 TOP1 CENPS CENPC CENPB CENPA
2 condensed chromosome kinetochore GO:0000777 9.54 CENPS CENPC CENPA
3 chromosome, centromeric region GO:0000775 9.46 CENPS CENPC CENPB CENPA
4 condensed nuclear chromosome kinetochore GO:0000778 9.26 CENPC CENPA
5 condensed nuclear chromosome, centromeric region GO:0000780 9.13 CENPC CENPB CENPA
6 nuclear pericentric heterochromatin GO:0031618 8.8 CENPC CENPB CENPA

Biological processes related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 9.5 TRIM21 IRF5 HLA-DRB1
2 regulation of regulatory T cell differentiation GO:0045589 9.43 IL2RA IL2
3 inflammatory response to antigenic stimulus GO:0002437 9.4 IL2RA HLA-DRB1
4 interleukin-2-mediated signaling pathway GO:0038110 9.37 IL2RA IL2
5 CENP-A containing nucleosome assembly GO:0034080 9.33 CENPS CENPC CENPA
6 negative regulation of lymphocyte proliferation GO:0050672 9.26 IL2RA IL2
7 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2RA IL2
8 kinetochore assembly GO:0051382 8.8 CENPS CENPC CENPA

Molecular functions related to Limited Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.61 TRIM21 TOP1 SCRT2 IRF5 IFI16 CENPS
2 centromeric DNA binding GO:0019237 8.62 CENPC CENPB

Sources for Limited Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....